Eli Lilly Reports Sofe-M Ovarian Cancer Data: 79% Response Rate
Eli Lilly announced new clinical data for investigational drug sofetabart mipitecan at the ESMO 2026 Congress in Madrid. The headline reports a 100% disease-control rate.
Eli Lilly & Co. (LLY) on Saturday announced new clinical data for its investigational ovarian cancer drug sofetabart mipitecan, or Sofe-M, at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid.The results come as Lilly continues to test Sofe-M in different types of ovarian can…